PMID- 29023765
OWN - NLM
STAT- MEDLINE
DCOM- 20180815
LR  - 20180815
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 142
IP  - 4
DP  - 2018 Feb 15
TI  - Impact of clinicopathological characteristics on the efficacy of neoadjuvant
      therapy in patients with human epidermal growth factor receptor-2-positive breast
      cancer.
PG  - 844-853
LID - 10.1002/ijc.31097 [doi]
AB  - Neoadjuvant therapy has become increasingly common in human epidermal growth
      factor receptor-2 (HER2)-positive breast cancer. In this study, we examined the
      impact of different clinicopathological characteristics on pathological complete 
      response (pCR) in patients treated with anti-HER2 agents. The PubMed and Embase
      databases were searched from inception through April 2017 to identify studies
      that met pre-specified criteria. The odds ratios (ORs) and 95% confidence
      intervals (CIs) were extracted directly or were calculated with other available
      information. Eleven randomized controlled trials (RCTs) that involved 3,269
      HER2-positive women were included in this meta-analysis. Patients with hormone
      receptor (HR)-negative breast cancer benefited more from anti-HER2 therapy than
      did patients with HR-positive tumours (OR, 2.25; 95% CI, 1.93-2.62). Furthermore,
      this improvement in pCR was independent of anti-HER2 agents, phase, combined
      chemotherapy, neoadjuvant duration, year the trials started and region where the 
      trials were conducted. Patients with small tumours achieved greater benefits than
      patients with large tumours (OR, 1.25; 95% CI, 1.00-1.55). Age did not predict an
      additional benefit from anti-HER2 neoadjuvant treatment (OR, 1.02; 95% CI,
      0.73-1.45). The impact of nodal status on pCR was dependent on the anti-HER2
      agents. In conclusion, for HER2-targeted neoadjuvant treatment in breast cancer, 
      greater benefits were achieved in patients with small HR-negative tumours
      compared with patients with large HR-positive tumours. These results may improve 
      drug development and treatment strategies, economic analyses and the design and
      interpretation of clinical trials.
CI  - (c) 2017 UICC.
FAU - Zhao, Bin
AU  - Zhao B
AUID- ORCID: 0000-0002-5990-1773
AD  - The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical
      University, Wenzhou, China.
FAU - Zhao, Hong
AU  - Zhao H
AD  - Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical
      University, Harbin, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20171025
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
EIN - Int J Cancer. 2019 May 1;144(9):E4. PMID: 30830985
MH  - Breast Neoplasms/*drug therapy/*enzymology
MH  - Chemotherapy, Adjuvant
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Randomized Controlled Trials as Topic
MH  - Receptor, ErbB-2/*biosynthesis
OTO - NOTNLM
OT  - *breast cancer
OT  - *human epidermal growth factor receptor-2
OT  - *neoadjuvant therapy
OT  - *pathological complete response
EDAT- 2017/10/13 06:00
MHDA- 2018/08/16 06:00
CRDT- 2017/10/13 06:00
PHST- 2017/04/26 00:00 [received]
PHST- 2017/10/02 00:00 [revised]
PHST- 2017/10/05 00:00 [accepted]
PHST- 2017/10/13 06:00 [pubmed]
PHST- 2018/08/16 06:00 [medline]
PHST- 2017/10/13 06:00 [entrez]
AID - 10.1002/ijc.31097 [doi]
PST - ppublish
SO  - Int J Cancer. 2018 Feb 15;142(4):844-853. doi: 10.1002/ijc.31097. Epub 2017 Oct
      25.